Impact of remission status in endogenous Cushing's syndrome on cancer incidence
Main finding · Malignancy risk in CDResult — go to the resultHazard ratio 3.89 95% CI 1.41–10.75Authors' conclusion
Though cancer risk is higher in both CD and adrenal CS, we have shown that achieving surgical remission within 2 years may attenuate cancer risk in patients with CD, but not in those with adrenal CS.
Study context
- Population
- Patients with endogenous Cushing's syndrome (CS) diagnosed 2000–2023 in Israel (Clalit Health Services' database); mean age at diagnosis 47.4 ± 16.8 years; 68.2% women388 cases · 1862 controls
- Participants
- 69 / 99 / 39 / 113 / 1,862
- Exposure
- No remission vs remission within 2 years postsurgery in CD and adrenal CS
- CD no remissionn = 69
- CD remissionn = 99reference
- Adrenal CS no early remissionn = 39
- Adrenal CS remissionn = 113reference
- Controlsn = 1,862reference
- Outcome
- Time to first diagnosis of malignancy, at least 3 years post-CS diagnosis
Methodological detailsnationwide, matched cohort, 1:5 matching by age, sex, socioeconomic status and BMI, competing-risk Cox proportional hazards
- Nationwide
- Matched cohort
- 1:5 matching by age, sex, socioeconomic status and BMI
- Competing-risk Cox proportional hazards
Main finding
Malignancy risk in CD
Hazard ratio
3.89
95% CI 1.41–10.75
CD no remissionvs CD remission
HR 3.89 (95% CI 1.41–10.75)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR for malignancy (95% CI) | |
|---|---|---|
| Malignancy risk: CD with remissionvs controls · ≥3 years post-CS diagnosisSimilar to controls · death as competing event | 0.58 (.23-1.47) | |
| Malignancy risk: adrenal CS withoutvs with early remission · ≥3 years post-CS diagnosisComparable | 1.68 (.83-3.40) | |
| 0.20.5125HR for malignancy (log scale) |
- Malignancy risk: adrenal CS without vs with early remission: n = 39 no early remission; n = 113 remission
Original publication
Impact of remission status in endogenous Cushing's syndrome on cancer incidence. Eur J Endocrinol. Published 25 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →